AU613297B2 - Strontium salt - Google Patents
Strontium salt Download PDFInfo
- Publication number
- AU613297B2 AU613297B2 AU37092/89A AU3709289A AU613297B2 AU 613297 B2 AU613297 B2 AU 613297B2 AU 37092/89 A AU37092/89 A AU 37092/89A AU 3709289 A AU3709289 A AU 3709289A AU 613297 B2 AU613297 B2 AU 613297B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- strontium
- distrontium salt
- salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 159000000008 strontium salts Chemical class 0.000 title description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000007868 Raney catalyst Substances 0.000 claims description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 3
- 229910003514 Sr(OH) Inorganic materials 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- SMPFVWIAMGUNEA-UHFFFAOYSA-N 4-(1,3-dicarboxypropan-2-yl)-3-methylpyrrole-1,2-dicarboxylic acid Chemical compound C(=O)(O)N1C(=C(C(=C1)C(CC(=O)O)CC(=O)O)C)C(=O)O SMPFVWIAMGUNEA-UHFFFAOYSA-N 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- RVBQDKIUVOWMLH-UHFFFAOYSA-N 3-[5-carboxy-1-(carboxymethyl)pyrrol-3-yl]pentanedioic acid Chemical compound OC(=O)CC(CC(O)=O)C=1C=C(C(O)=O)N(CC(O)=O)C=1 RVBQDKIUVOWMLH-UHFFFAOYSA-N 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229910052712 strontium Inorganic materials 0.000 description 7
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MYTYHLDSYLKPSF-UHFFFAOYSA-N 6h-thieno[2,3-b]pyrrole Chemical class C1=CSC2=C1C=CN2 MYTYHLDSYLKPSF-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910001631 strontium chloride Inorganic materials 0.000 description 3
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- -1 thieno[2,3-b]pyrrole compound Chemical class 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000830713 Homo sapiens Torsin-3A Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100024603 Torsin-3A Human genes 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UZDTXABVOIIREX-UHFFFAOYSA-N (z)-[4-diazonio-2-ethoxycarbonyl-3-(2-ethoxy-2-oxoethyl)thieno[2,3-b]pyrrol-5-ylidene]-ethoxymethanolate Chemical compound CCOC(\[O-])=C/1C([N+]#N)=C2C(CC(=O)OCC)=C(C(=O)OCC)SC2=N\1 UZDTXABVOIIREX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- CYUUCQHMPCRIQA-UHFFFAOYSA-N diethyl 3-(2-ethoxy-2-oxoethyl)-6h-thieno[2,3-b]pyrrole-2,5-dicarboxylate Chemical compound N1C(C(=O)OCC)=CC2=C1SC(C(=O)OCC)=C2CC(=O)OCC CYUUCQHMPCRIQA-UHFFFAOYSA-N 0.000 description 1
- PHMPRBVCRMBBJA-UHFFFAOYSA-N diethyl 3-[5-ethoxycarbonyl-1-(2-ethoxy-2-oxoethyl)pyrrol-3-yl]pentanedioate Chemical compound CCOC(=O)CC(CC(=O)OCC)C=1C=C(C(=O)OCC)N(CC(=O)OCC)C=1 PHMPRBVCRMBBJA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- JLVXEEDLNOGPBY-UHFFFAOYSA-N ethyl 2-[2,5-di(propanoyl)-6h-thieno[2,3-b]pyrrol-3-yl]acetate Chemical compound N1C(C(=O)CC)=CC2=C1SC(C(=O)CC)=C2CC(=O)OCC JLVXEEDLNOGPBY-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006390 lc 2 Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QRVYVKGHSWMAJI-IYEMJOQQSA-L strontium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Sr+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O QRVYVKGHSWMAJI-IYEMJOQQSA-L 0.000 description 1
- CCUZKVDGQHXAFK-UHFFFAOYSA-L strontium;2-hydroxypropanoate Chemical compound [Sr+2].CC(O)C([O-])=O.CC(O)C([O-])=O CCUZKVDGQHXAFK-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Light Receiving Elements (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8808729A FR2633619B1 (fr) | 1988-06-29 | 1988-06-29 | Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant |
| FR8808729 | 1988-06-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3709289A AU3709289A (en) | 1990-01-04 |
| AU613297B2 true AU613297B2 (en) | 1991-07-25 |
Family
ID=9367847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU37092/89A Ceased AU613297B2 (en) | 1988-06-29 | 1989-06-28 | Strontium salt |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4939164A (enExample) |
| EP (1) | EP0349432B1 (enExample) |
| JP (1) | JPH0248567A (enExample) |
| AT (1) | ATE81118T1 (enExample) |
| AU (1) | AU613297B2 (enExample) |
| CA (1) | CA1312333C (enExample) |
| DE (1) | DE68903059T2 (enExample) |
| DK (1) | DK325289A (enExample) |
| ES (1) | ES2044170T3 (enExample) |
| FR (1) | FR2633619B1 (enExample) |
| GR (1) | GR3006674T3 (enExample) |
| IE (1) | IE64112B1 (enExample) |
| NZ (1) | NZ229760A (enExample) |
| OA (1) | OA09121A (enExample) |
| PT (1) | PT91006B (enExample) |
| ZA (1) | ZA894945B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
| FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| DK1622630T3 (da) * | 2003-05-07 | 2012-12-17 | Osteologix As | P009368epdk1 |
| ATE342722T1 (de) * | 2003-05-07 | 2006-11-15 | Osteologix As | Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen |
| PL1732575T3 (pl) | 2004-02-26 | 2011-05-31 | Osteologix As | Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości |
| US8658206B2 (en) | 2004-06-25 | 2014-02-25 | Mokwalo SA | Compositions comprising strontium and vitamin D and uses thereof |
| US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
| WO2016058824A1 (en) | 2014-10-14 | 2016-04-21 | Unilever N.V. | Spraying device |
| WO2016058753A1 (en) | 2014-10-14 | 2016-04-21 | Unilever N.V. | Device for spraying an enclosure triggered by inclination of a rotatable lid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2954384A (en) * | 1960-09-27 | Method for preparing kainic acid and its | ||
| DE3127275A1 (de) * | 1980-12-11 | 1983-01-27 | Leskovar, Peter, Dr.-Ing., 8000 München | "harnsteinaufloesende mittel" |
-
1988
- 1988-06-29 FR FR8808729A patent/FR2633619B1/fr not_active Expired - Lifetime
-
1989
- 1989-06-20 US US07/368,593 patent/US4939164A/en not_active Expired - Fee Related
- 1989-06-26 ZA ZA894945A patent/ZA894945B/xx unknown
- 1989-06-27 CA CA000604039A patent/CA1312333C/fr not_active Expired - Fee Related
- 1989-06-28 PT PT91006A patent/PT91006B/pt not_active IP Right Cessation
- 1989-06-28 OA OA59600A patent/OA09121A/xx unknown
- 1989-06-28 AU AU37092/89A patent/AU613297B2/en not_active Ceased
- 1989-06-28 NZ NZ229760A patent/NZ229760A/en unknown
- 1989-06-28 IE IE209489A patent/IE64112B1/en not_active IP Right Cessation
- 1989-06-29 DE DE8989401861T patent/DE68903059T2/de not_active Expired - Fee Related
- 1989-06-29 EP EP89401861A patent/EP0349432B1/fr not_active Expired - Lifetime
- 1989-06-29 AT AT89401861T patent/ATE81118T1/de not_active IP Right Cessation
- 1989-06-29 DK DK325289A patent/DK325289A/da not_active Application Discontinuation
- 1989-06-29 JP JP1168247A patent/JPH0248567A/ja active Granted
- 1989-06-29 ES ES89401861T patent/ES2044170T3/es not_active Expired - Lifetime
-
1992
- 1992-12-24 GR GR920403112T patent/GR3006674T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3709289A (en) | 1990-01-04 |
| PT91006B (pt) | 1994-11-30 |
| FR2633619A1 (fr) | 1990-01-05 |
| EP0349432B1 (fr) | 1992-09-30 |
| ES2044170T3 (es) | 1994-01-01 |
| US4939164A (en) | 1990-07-03 |
| DK325289D0 (da) | 1989-06-29 |
| FR2633619B1 (fr) | 1991-02-08 |
| CA1312333C (fr) | 1993-01-05 |
| DE68903059T2 (de) | 1993-04-29 |
| EP0349432A1 (fr) | 1990-01-03 |
| PT91006A (pt) | 1989-12-29 |
| GR3006674T3 (enExample) | 1993-06-30 |
| JPH0248567A (ja) | 1990-02-19 |
| ATE81118T1 (de) | 1992-10-15 |
| JPH0587064B2 (enExample) | 1993-12-15 |
| DK325289A (da) | 1989-12-30 |
| IE892094L (en) | 1989-12-29 |
| OA09121A (fr) | 1991-10-31 |
| ZA894945B (en) | 1990-03-28 |
| DE68903059D1 (de) | 1992-11-05 |
| NZ229760A (en) | 1991-06-25 |
| IE64112B1 (en) | 1995-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU624022B2 (en) | New divalent metal salts of 2-(n,n-di(carboxymethyl)amino) -3-cyano-4-carboxymethylthiophene-5-carboxylic acid, a process for the preparation thereof, and pharmaceutical compositions containing them | |
| DE69524114T2 (de) | Naphthyridinonderivate | |
| US4299838A (en) | Tryptophan derivatives having an increased effect on the central nervous system | |
| AU613297B2 (en) | Strontium salt | |
| FI82044C (fi) | Foerfarande foer framstaellning av ett terapeutiskt aktivt doxepin-, pyridoxin-,2-guanidino-4-(2-metyl-4- imidazolyl)tiazol-, pirbuterol-, isoproterenol- eller trimazosinsalt av piroxicam. | |
| FI96421B (fi) | Menetelmä substituoidun karboksyylihapon farmaseuttisesti käyttökelpoisen kodeiinisuolan valmistamiseksi | |
| FI63568B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat | |
| EP0894794A1 (en) | Optical isomers of cloperastine | |
| CN1128999A (zh) | 杂环化合物 | |
| US4076815A (en) | Quinoxaline compound and composition, process for preparing compound, and method of combatting cholera therewith | |
| US3923996A (en) | 3-Substituted-oxindoles in compositions and methods of treating obesity | |
| CA1147746A (en) | 2-amino-3-(alkylthiobenzoyl)phenylacetic acids | |
| US4076714A (en) | 1-Methyl-4-(2-carboxy-thioxanthen-9-ylidene)-piperidine an appetite stimulant and antihistaminic agent | |
| US3290375A (en) | Naphthamidines and salts thereof | |
| JPS6320426B2 (enExample) | ||
| RU2068415C1 (ru) | 5,7-диокси-2-метил-8-/4-(3-окси-1-(1-пропил)пиперидинил/-4н-1-бензопиран-4-он или его стереоизомеры или фармакологически приемлемые кислотно-аддитивные соли и способ их получения | |
| JPS63156723A (ja) | 骨粗鬆症治療剤 | |
| EP0467599A1 (en) | N-Alkyl thiazolidine derivatives | |
| US4215143A (en) | Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient | |
| SU1072809A3 (ru) | Способ получени тиадиазолтетрагидроизохинолина или его фармацевтически приемлемой кислотно-аддитивной соли | |
| US5011974A (en) | Process for the preparation of derivative of 2-diethylamino-1-methylethyl-1-hydroxy-(bicyclohexyl)-2-carboxylate | |
| CA1138776A (en) | Process for producing d-penicillamine and preparation containing same | |
| JPH0629184B2 (ja) | 骨粗鬆症治療剤 | |
| DE2442910A1 (de) | Neue derivate von phenylessigsaeure, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die die derivate als wirkstoffe enthalten | |
| WO1994017068A1 (en) | Tricyclic 1,2,4-triazolo compounds with anti-inflammatory and immunomodulatory properties |